HSA
BLUE

HBK Sorce Advisory’s bluebird bio BLUE Stock Holding History

HBK Sorce Advisory’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,019
Closed -$10.6K – 583
2024
Q3 		$10.6K Buy
1,019
+287
+39% +$4.77K ﹤0.01% 578
2024
Q2 		$14.4K Buy
732
+114
+18% +$2.28K ﹤0.01% 561
2024
Q1 		$15.8K Buy
+618
New +$15.8K ﹤0.01% 598

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HBK Sorce Advisory's BLUE Position: Q4 2024 in Review

HBK Sorce Advisory sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 1,019 shares — an estimated $10.6K sold.

HBK Sorce Advisory first reported a position in BLUE in Q1 2024 and held it in 3 quarters. The position peaked at $15.8K in Q1 2024. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • HBK Sorce Advisory reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • HBK Sorce Advisory sold 1,019 bluebird bio shares in Q4 2024, an estimated $10.6K.
  • HBK Sorce Advisory first reported a position in bluebird bio in Q1 2024 and held it in 3 quarters.
  • HBK Sorce Advisory's bluebird bio position peaked at $15.8K in Q1 2024.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on HBK Sorce Advisory's 13F filing for Q4 2024, filed 10 Feb 2025.